Squarepoint
TNYA icon

Squarepoint’s Tenaya Therapeutics TNYA Stock Holding History

Squarepoint’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Buy
659,247
+310,979
+89% +$236K ﹤0.01% 3447
2026
Q1 		$241K Buy
+348,268
New +$257K ﹤0.01% 3854
2025
Q4 		– Sell
-36,253
Closed -$58.7K – 4899
2025
Q3 		$58.7K Sell
36,253
-347,554
-91% -$350K ﹤0.01% 4203
2025
Q2 		$235K Buy
383,807
+286,274
+294% +$146K ﹤0.01% 3871
2025
Q1 		$55.6K Buy
97,533
+66,542
+215% +$65.7K ﹤0.01% 4326
2024
Q4 		$44.3K Sell
30,991
-175,425
-85% -$393K ﹤0.01% 4863
2024
Q3 		$398K Buy
206,416
+85,712
+71% +$242K ﹤0.01% 3266
2024
Q2 		$374K Buy
120,704
+55,816
+86% +$231K ﹤0.01% 3285
2024
Q1 		$339K Sell
64,888
-80,607
-55% -$386K ﹤0.01% 3310
2023
Q4 		$471K Buy
145,495
+118,312
+435% +$255K ﹤0.01% 3046
2023
Q3 		$69.3K Buy
+27,183
New +$114K ﹤0.01% 3604
2023
Q1 		– Sell
-61,167
Closed -$123K – 3821
2022
Q4 		$123K Buy
+61,167
New +$149K ﹤0.01% 2932

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's TNYA Position: Q2 2026 in Review

Squarepoint increased its Tenaya Therapeutics (TNYA) stake by 89% in Q2 2026, buying an estimated $236K and bringing the position to 659,247 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #3447.

Squarepoint first reported a position in TNYA in Q4 2022 and has held it in 12 quarters since. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Squarepoint held 659,247 shares of Tenaya Therapeutics worth $487K as of Q2 2026.
  • Squarepoint bought 310,979 Tenaya Therapeutics shares in Q2 2026, an estimated $236K.
  • Tenaya Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3447 holding.
  • Squarepoint first reported a position in Tenaya Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.